加藤健 (Ken Kato) - マイポータル

基本情報

所属: 国立研究開発法人国立がん研究センター中央病院頭頸部食道内科/消化管内科科長

J-GLOBAL ID: 201801015816250361
researchmap会員ID: B000316133

研究分野

ライフサイエンス / 腫瘍診断、治療学 /

論文

340

An Integrated Individual Patient-Level Database from JCOG Trials in Esophageal Cancer: A Research Platform (JCOG2512A)

Kota Kawabata, Satoru Matsuda, Takahiro Tsushima, Koshiro Ishiyama, Yuya Ishikawa, Ryunosuke Machida, Takeshi Uozumi, Keita Sasaki, Haruhiko Fukuda, Ken Kato …

European Journal of Surgical Oncology 111962-111962 2026年6月
Retrospective comparison of capecitabine plus oxaliplatin and docetaxel plus S-1 as adjuvant chemotherapy for pathological stage III gastric cancer.

Toru Imai, Hidekazu Hirano, Hirokazu Shoji, Toshiharu Hirose, Natsuko Okita, Atsuo Takashima, Ken Kato

Oncology 1-19 2026年5月21日
Bridging the Evidence Gap in Small Bowel Adenocarcinoma: Current Standards, Biomarker-selected Therapies and Novel Antibody–Drug Conjugate-based Clinical Initiatives

Hiroyuki Fuji, Hidekazu Hirano, Hirokazu Shoji, Natsuko Okita, Ken Kato

touchREVIEWS in Oncology & Haematology 22(1) 2026年4月
Prognostic Impact of Postoperative Complications After Neoadjuvant Therapy Followed by Esophagectomy for Esophageal Cancer

Eisuke Booka, Ken Kato, Yoshinori Ito, Hiroyuki Daiko, Kazuo Koyanagi, Miho Yamamoto, Takashi Ogata, Takashi Fukuda, Takeo Fujita, Tetsuya Abe …

Annals of Surgery 2026年3月6日
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Jun Okui, Satoru Matsuda, Kengo Nagashima, Yasunori Sato, Hirofumi Kawakubo, Thomas Ruhstaller, Peter Thuss-Patience, Magnus Nilsson, Fredrik Klevebro, Lijie Tan …

British Journal of Surgery 2026年2月17日
Implementing generative artificial intelligence in precision oncology: safety, governance, and significance.

Ryuji Hamamoto, Takafumi Koyama, Satoshi Takahashi, Tomohiro Yasuda, Kazuma Kobayashi, Yu Akagi, Nobuji Kouno, Kazuki Sudo, Makoto Hirata, Kuniko Sunami …

Journal of hematology & oncology 19(1) 14-14 2026年2月9日
Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109

Ryosuke Kita, Ken Kato, Ryunosuke Machida, Yoshinori Ito, Hiroyuki Daiko, Hirofumi Kawakubo, Keita Sasaki, Haruhiko Fukuda, Yasue Kimura, Kohei Akiyoshi …

Annals of Surgical Oncology 2026年1月14日
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials

Jun Okui, Satoru Matsuda, Kengo Nagashima, Yasunori Sato, Hirofumi Kawakubo, Thomas Ruhstaller, Peter Thuss-Patience, Magnus Nilsson, Fredrik Klevebro, Lijie Tan …

JNCI: Journal of the National Cancer Institute 2026年1月8日
Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan

Nozomu Ogura, Hidekazu Hirano, Kouya Shiraishi, Hiroyuki Fujii, Toshiharu Hirose, Hirokazu Shoji, Natsuko Okita, Atsuo Takashima, Takafumi Koyama, Kan Yonemori …

JCO Precision Oncology (10) 2026年1月
Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial

Motoo Nomura, Katsuyuki Sakanaka, Juko Shimizu, Shinya Ohashi, Chikatoshi Katada, Akinori Watanabe, Yusuke Amanuma, Keiko Minashi, Ken Kato, Takashi Kojima …

eClinicalMedicine 91 103689-103689 2026年1月
Definition and treatment strategies for oligometastatic esophageal squamous cell carcinoma (OMESQ): a study protocol for global multidisciplinary consensus using the modified Delphi method

Motoo Nomura, Ken Kato, Takashi Ogata, Mitsuro Kanda, Yoichi Hamai, Yasuhiro Tsubosa, Takako Yoshii, Mitsuhiro Furuta, Katsuyuki Sakanaka, Satoru Matsuda …

ANNALS OF ESOPHAGUS 8 2025年12月30日
Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Yuri Yoshinami, Shotaro Yamaguchi, Hirokazu Shoji, Natsuko Okita, Hiroyuki Takamaru, Toshiharu Hirose, Hidekazu Hirano, Atsuo Takashima, Hiroshi Imazeki, Shun Yamamoto …

Future oncology (London, England) 1-10 2025年12月17日
Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer

Hirokazu Shoji, Daisuke Takahari, Akira Ooki, Hidekazu Hirano, Natsuko Okita, Kengo Nagashima, Jun Adachi, Kensei Yamaguchi, Ken Kato, Narikazu Boku

Scientific Reports 2025年12月5日査読有り
Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).

Katsuyuki Sakanaka, Keita Sasaki, Takahiro Tsushima, Ryunosuke Machida, Yoichi Hamai, Akinori Watanabe, Kota Kawabata, Satoru Matsuda, Ken Kato, Haruhiko Fukuda …

BMC cancer 2025年12月3日
401P Comparison of efficacy and safety of capecitabine plus mitomycin, 5-FU plus mitomycin, and 5-FU plus cisplatin regimens for definitive chemoradiotherapy in anal squamous cell carcinoma: A single-center retrospective study

T. Sanomachi, A. Takashima, H. Hirano, M. Miyake, K. Okuma, S. Yamaguchi, T. Hirose, H. Shoji, N.T. Okita, K. Kato

Annals of Oncology 36 S1885-S1885 2025年12月
Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma

Kazuhiro Shiraishi, Shun Yamamoto, Toshiharu Hirose, Hiroshi Imazeki, Kazuki Yokoyama, Yoshitaka Honma, Taiki Hashimoto, Tairo Kashihara, Daisuke Kurita, Koshiro Ishiyama …

Esophagus 2025年11月7日
A Retrospective Analysis of the Efficacy and Safety of Imatinib for Advanced Gastrointestinal Stromal Tumor in Elderly Patients

Takahito Awatsu, Hidekazu Hirano, Kengo Nagashima, Toshiharu Hirose, Natsuko Okita, Hirokazu Shoji, Atsuo Takashima, Akihito Nagahara, Ken Kato

Cancer Medicine 14(21) 2025年10月31日
Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma

Yuri Yoshinami, Shun Yamamoto, Kazuhiro Shiraishi, Hiroshi Imazeki, Kazuki Yokoyama, Yoshitaka Honma, Daisuke Kurita, Koshiro Ishiyama, Junya Oguma, Taiki Hashimoto …

Esophagus 2025年10月14日
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer

Jun Okui, Satoru Matsuda, Kengo Nagashima, Yasunori Sato, Hirofumi Kawakubo, Thomas Ruhstaller, Peter Thuss-Patience, Magnus Nilsson, Fredrik Klevebro, Lijie Tan …

Annals of Surgery 2025年8月25日
First-Line Docetaxel Once Every 2 Weeks With Cisplatin Plus Fluorouracil for Metastatic Esophageal Cancer: A Multicenter, Randomized Controlled Phase III Study (JCOG1314, MIRACLE)

Takahiro Tsushima, Shuichi Hironaka, Yasuhiro Tsubosa, Ryunosuke Machida, Ken Kato, Shigenori Kadowaki, Motoo Nomura, Hiroki Hara, Yuko Kitagawa, Kazuo Koyanagi …

JCO Oncology Advances (2) 2025年8月

もっとみる

MISC

117

Randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for metastatic or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).

Katsuyuki Sakanaka, Keita Sasaki, Takahiro Tsushima, Ryunosuke Machida, Yoichi Hamai, Akinori Watanabe, Kota Kawabata, Satoru Matsuda, Ken Kato, Haruhiko Fukuda …

JOURNAL OF CLINICAL ONCOLOGY 44(2_SUPPL) TPS461-TPS461 2026年1月
肛門扁平上皮癌に対する根治的化学放射線療法レジメンとしてのCapecitabine+Mitomycinの有効性と安全性:単施設後方視的研究

佐野町友美, 高島淳生, 平野秀和, 三宅基隆, 大熊加惠, 山口翔太郎, 廣瀬俊晴, 庄司広和, 沖田南都子, 加藤健

大腸癌研究会学術集会プログラム・抄録集 102nd 2025年
Prognostic factors for overall survival in patients with advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: A post-hoc analysis of JCOG1213

Hidekazu Hirano, Kenro Hirata, Yoshitaka Honma, Chigusa Morizane, Nozomu Machida, Ken Kato, Takuji Okusaka, Narikazu Boku, Shigeki Sekine, Nobuyoshi Hiraoka …

JOURNAL OF CLINICAL ONCOLOGY 42(3_SUPPL) 594-594 2024年1月20日
A randomized controlled phase III trial of comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer:JCOG1904/ARMADILLO study.

Motoo Nomura, Katsuyuki Sakanaka, Ken Kato, Tomohiro Kadota, Yoshinori Ito, Ryunosuke Machida, Keita Sasaki, Tomoko Kataoka, Yasumasa Nishimura, Yuko Kitagawa

JOURNAL OF CLINICAL ONCOLOGY 39(3) 2021年1月
Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: Supplementary analysis of the JCOG trial, JCOG0502.

Seiichiro Mitani, Ken Kato, Hiroyuki Daiko, Isao Nozaki, Takashi Kojima, Masahiko Yano, Satoru Nakagawa, Masaki Ueno, Masaya Watanabe, Shigeru Tsunoda …

JOURNAL OF CLINICAL ONCOLOGY 38(15) 2020年5月
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.

Tomoya Yokota, Ken Kato, Yasuo Hamamoto, Yasuhiro Tsubosa, Hirofumi Ogawa, Yoshinori Ito, Hiroki Hara, Takashi Ura, Takashi Kojima, Keisho Chin …

Annals of surgical oncology 27(2) 460-467 2020年2月
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki …

The Lancet. Oncology 20(11) 1506-1517 2019年11月
食道癌に対する根治的CRTとNivolumab併用による医師主導治験 Trial in progress

野村基雄, 清水充子, 大橋真也, 三梨桂子, 加藤健, 小島隆嗣, 坂中克行, 武藤学

日本癌治療学会学術集会抄録集 57回 P9-5 2019年10月
食道癌に対するnivolumabと化学放射線療法(NOBEL) 治験進行中(NivOlumaB and chemoradiotherapy for EsophageaL cancer(NOBEL)(Trial in progress))

野村基雄, 清水充子, 大橋真也, 三梨桂子, 加藤健, 小島隆嗣, 坂中克行, 武藤学

日本食道学会学術集会プログラム・抄録集 73回 232-232 2019年6月
TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.

Hideaki Bando, Daisuke Kotani, Takahiro Tsushima, Hiroki Hara, Shigenori Kadowaki, Ken Kato, Keisho Chin, Kensei Yamaguchi, Shun-ichiro Kageyama, Hidehiro Hojo …

JOURNAL OF CLINICAL ONCOLOGY 37(15) 2019年5月
bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).

Yoshiaki Nakamura, Yoshito Komatsu, Ken Kato, Eiji Shinozaki, Hideaki Bando, Takeshi Kato, Tomohiro Nishina, Taito Esaki, Shogo Nomura, Gakuto Ogawa …

JOURNAL OF CLINICAL ONCOLOGY 37(4) 2019年2月
Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer.

Takao Iemoto, Shin Nishiumi, Takashi Kobayashi, Seiji Fujigaki, Tetsuya Hamaguchi, Ken Kato, Hirokazu Shoji, Yasuhiro Matsumura, Kazufumi Honda, Masaru Yoshida

Oncology letters 17(1) 831-842 2019年1月
Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer.

Madoka Nambu, Takeshi Masuda, Shingo Ito, Ken Kato, Takashi Kojima, Hiroyuki Daiko, Yoshinori Ito, Kazufumi Honda, Sumio Ohtsuki

Biological & pharmaceutical bulletin 42(10) 1766-1771 2019年
Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach.

Seiji Fujigaki, Shin Nishiumi, Takashi Kobayashi, Makoto Suzuki, Takao Iemoto, Takashi Kojima, Yoshinori Ito, Hiroyuki Daiko, Ken Kato, Hirokazu Shouji …

Biomarkers in medicine 12(8) 827-840 2018年8月
化学放射線療法の現状と新たなる展望〜制癌剤と照射法の工夫〜臨床病期II/III食道癌に対する根治的化学放射線療法+/-救済治療第II相試験(JCOG0909)

竹内裕也, 伊藤芳紀, 加藤健, 小野澤正勝, 三梨桂子, 矢野友規, 對馬隆浩, 小川岳人, 片山宏, 北川雄光

日本食道学会学術集会プログラム・抄録集 72回 55-55 2018年6月
食道癌化学放射線療法後の局所遺残・再発に対する内視鏡切除の成績および再発危険因子

江郷茉衣, 阿部清一郎, 吉永繁高, 小田一郎, 加藤健, 本間義崇, 伊藤芳紀, 伊丹純, 大幸宏幸, 朴成和

日本食道学会学術集会プログラム・抄録集 72回 225-225 2018年6月
The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.

Satoshi Yuki, Kentaro Yamazaki, Hiroya Taniguchi, Yu Sunakawa, Akihito Kawazoe, Yoshinori Kagawa, Ken Kato, Hiroki Hara, Tadamichi Denda, Eiji Oki …

JOURNAL OF CLINICAL ONCOLOGY 36(4) 2018年2月
Retrospective observational study of salvage line ramucirumab monotherapy (RAM) for patients (pts) with unresectable advanced gastric cancer (AGC) which was refractory to fluoropyrimidine and taxanes

Naoki Fukuda, Sadayuki Kawai, Katsuhiro Omae, Seiichiro Mitani, Takeru Wakatsuki, Ken Kato, Shigenori Kadowaki, Daisuke Takahari, Narikazu Boku, Kei Muro …

JOURNAL OF CLINICAL ONCOLOGY 36(4) 2018年2月
ECTAS: A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies

Takahiro Tsushima, Hiroi Kasai, Takashi Kojima, Hiroki Hara, Yukiko Mori, Ryu Ishihara, Ken Kato, Shuichi Hironaka, Harue Tada, Manabu Muto

ANNALS OF ONCOLOGY 28 2017年10月
Risk Factor Analyses of Severe Cicatricial Stricture after Chemoradiotherapy for Stage II/III (T3) Esophageal Carcinoma

Natsuko Kitamura (Tsushita), Yoshitaka Honma, Kengo Nagashima, Hirokazu Shoji, Atsuo Takashima, Satoru Iwasa, Ken Kato, Tetsuya Hamaguchi, Jun Itami, Narikazu Boku

ANNALS OF ONCOLOGY 28 2017年10月

もっとみる

書籍等出版物

術前化学療法と術前化学放射線療法は，効果・安全性の面からどちらが良いか？

加藤健 (担当:分担執筆)

医事新報社 2017年

講演・口頭発表等

A randomized controlled phase III comparing CF (5-FU, CDDP) versus DCF (5-FU, CDDP, docetaxel) versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancer

加藤健

International Symposium of Disease of Esophagus 2018年6月

共同研究・競争的資金等の研究課題

アブスコパル効果を利用した革新的放射線免疫療法の開発と新規バイオマーカー探索研究

日本学術振興会科学研究費助成事業基盤研究(B) 2024年4月 - 2029年3月

坂中克行, 渡邉翼, 竹内裕也, 加藤健, 對馬隆浩
抗体医薬品によるインフュージョン反応の発現メカニズム解析と予測系の構築

日本学術振興会科学研究費助成事業基盤研究(B) 2011年4月 - 2014年3月

斎藤嘉朗, 石井明子, 加藤健, 黒瀬光一, 中村亮介, 多田稔, 杉山永見子

加藤健

基本情報

研究分野

論文

MISC

書籍等出版物

講演・口頭発表等

共同研究・競争的資金等の研究課題

メニュー

共著者の一覧